GC Green Cross Wellbeing Signs Export Contract for hADM Acellular Allogenic Dermis 'GCELLE REBORNNE' to Japan

by Jeong Donghoon

Published 07 Apr.2026 12:44(KST)

GC Green Cross Wellbeing announced on April 7 that it has signed an export contract for its human tissue-based acellular allogenic dermis product, 'GCELLE REBORNNE', to Japan, accelerating the expansion of its medical aesthetics business in the Asian market.

After signing the MOU, Keita Goto, CEO of Nifuji (left), and Sanghyun Kim, CEO of GC Green Cross Wellbeing, are taking a commemorative photo. GC Green Cross Wellbeing

GC Green Cross Wellbeing has entered into a supply agreement with its local Japanese partner, Nifuji, and will begin full-scale cooperation in distribution and marketing within Japan. This partnership is significant as it establishes a stable distribution base in the Japanese market.

The company has simultaneously launched the product domestically and entered the Japanese market, with full-scale product supply beginning in March. Additionally, starting in May, the company plans to hold a symposium for Japanese healthcare professionals to raise product awareness and conduct academic marketing targeting medical professionals.

'GCELLE REBORNNE' is a product based on human acellular dermal matrix (hADM), a material derived from human tissue. Its distinguishing feature is the application of a processing technique that minimizes tissue damage, thereby enhancing biocompatibility.

GC Green Cross Wellbeing plans to solidify Japan, which offers both growth potential and stability, as a core strategic market and to accelerate expansion into the broader Asian and global markets. In particular, the company aims to actively promote its differentiated technology based on acellular allogenic dermis through close collaboration with local partners, thereby making a strong entry into Asian and global markets.

A representative from GC Green Cross Wellbeing stated, "GC Green Cross Wellbeing has the expertise gained from successfully launching Laennec, a placental extract product, in the market. We plan to actively promote the differentiated technological strengths of GCELLE REBORNNE and rapidly expand our presence within the Asian market."

Meanwhile, on March 31, GC Green Cross Wellbeing successfully held a launch symposium for 'GCELLE REBORNNE' with 150 medical professionals in attendance, sharing a new paradigm in skin treatment and various clinical application cases. The company plans to continue to provide differentiated treatment solutions through ongoing academic activities.